Evidence map›Paper›PMID 37004272›Full record

ArticleMultiple sclerosis and related disorders2023

Quantitative MRI identifies lesional and non-lesional abnormalities in MOGAD.

Matthew R Brier, Biao Xiang, John R Ciotti, Salim Chahin, Gregory F Wu, Robert T Naismith, Dmitriy Yablonskiy, Anne H Cross

Open access · greenAbstract read
In one paragraph

Article in Multiple sclerosis and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. MOG Antibody Disease: Nuances in Presentation, Diagnosis, and Management.Current neurology and neuroscience reports · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Matthew R BrierDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, United States.
Biao XiangMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, United States.
John R CiottiDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, United States; Department of Neurology, University of South Florida, Tampa, FL, United States.
Salim ChahinDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, United States.
Gregory F WuDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, United States.
Robert T NaismithDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, United States.
Dmitriy YablonskiyMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, United States.
Anne H CrossDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, United States. Electronic address: crossa@wustl.edu.
Washington University in St. Louis · US

Funding

Washington University Institute of Clinical and Translational Sciences (KL2) KL2TR002346 · NCATS · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 2017 to 2026
$14.0M
In vivo MRI Biomarkers of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer DiseaseR01AG054513 · NIA · WASHINGTON UNIVERSITY · PI YABLONSKIY, DMITRIY A · 2017 to 2021
$2.7M
In vivo Identification of Pre-Atrophic Brain Neurodegeneration in Prodromal Alzheimer Disease with Quantitative Gradient Recalled Echo MRIRF1AG077658 · NIA · WASHINGTON UNIVERSITY · PI YABLONSKIY, DMITRIY A · 2022 to 2022
$2.2M
WASHINGTON UNIVERSITY NEUROSURGERY RESIDENT RESEARCH EDUCATION PROGRAMR25NS090978 · NINDS · WASHINGTON UNIVERSITY · PI ZIPFEL, GREGORY J · 2015 to 2023
$2.1M
Using quantitative gradient echo MRI to distinguish MOG antibody disorder from multiple sclerosisR03NS121960 · NINDS · WASHINGTON UNIVERSITY · PI CROSS, DOROTHY ANNE · 2021 to 2021
$158k
NCATS NIH HHS KL2 TR002346NIA NIH HHS R01 AG054513NIA NIH HHS RF1 AG077658NINDS NIH HHS R03 NS121960NINDS NIH HHS R25 NS090978
6 · The paper itself

Abstract

backgroundMyelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a distinct central nervous system (CNS) disorder that shares features with multiple sclerosis (MS) and may be misdiagnosed as MS. MOGAD and MS share a frequently relapsing clinical course and lesions with inflammatory demyelinating pathology. One key feature of MS pathology is tissue damage in normal-appearing white matter (NAWM) outside of discrete lesions, whereas the extent to which similar non-lesional damage occurs in MOGAD is not known and could be assessed using qGRE. The goal of this study was to examine the brains of people with MOGAD using quantitative gradient-recalled echo (qGRE) magnetic resonance imaging and to compare tissue damage with MS patients matched for disability.

methodsMOGAD and MS patients were recruited to match in terms of age and disability. Similarly aged healthy control (HC) data were drawn from existing studies. qGRE brain imaging of HC (N = 15), MOGAD (N = 17), and MS (N = 15) patients was used to examine the severity and extent of tissue damage within and outside of discrete lesions. The qGRE metric R2t* is sensitive to changes in tissue microstructure and was measured in white matter lesions (WMLs), NAWM, cortical (CGM) and deep gray matter (DGM). Statistical inference was performed with linear models.

resultsR2t* was reduced in CGM (p = 0.00047), DGM (p = 0.0055) and NAWM (p = 0.0019) in MOGAD and MS compared to similar regions in age-matched HCs. However, the degree of R2t* reduction in all these regions was less in the MOGAD patients compared with MS. WMLs in MOGAD demonstrated reduced R2t* compared to NAWM but this reduction was modest compared to changes associated with WMLs in MS (p = 0.026).

conclusionThese results demonstrate abnormalities in lesional and non-lesional CNS tissues in MOGAD that are not detectable on standard MRI. The abnormalities seen in NAWM, CGM, and DGM were less severe in MOGAD compared to MS. MOGAD-related WMLs showed reduced R2t*, but were less abnormal than WMLs in MS. These data reveal damage to non-lesional tissues in two different demyelinating diseases, suggesting that damage outside of WMLs may be a common feature of demyelinating diseases. The lesser degree of R2t* abnormality in MOGAD tissues compared to MS suggests less underlying tissue damage and may underlie the greater propensity for recovery in MOGAD.

Indexed as

Central Nervous System DiseasesMultiple SclerosisWhite MatterBrainHumansMagnetic Resonance ImagingMultiple sclerosisMyelin oligodendrocyte glycoprotein antibody-associated diseaseqGREQuantitative gradient recalled echo imaging

Identifiers

PMID37004272
PMCPMC10994694
OpenAlexW4353051732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.